Staff, Endocrinology and Metabolism Institute, Cleveland Clinic, Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
Professor of Medicine, CWRU School of Medicine, Vice Chair, UH System Clinical Affairs, Department of Medicine, Medical Director, Diabetes & Obesity Center, Mary B. Lee Chair in Adult Endocrinology, University Hospitals Cleveland Medical Center, Cleveland, OH
Cleve Clin J Med. 2021 Nov 2;88(11):635-639. doi: 10.3949/ccjm.88a.18069.
In a perimenopausal or postmenopausal woman, an elevation in human chorionic gonadotropin (hCG) can raise the concern of malignancy or even pregnancy, but it can also be a benign physiologic finding due to production in the pituitary gland in this patient population. Diagnosing the underlying cause of hCG elevation can be challenging, especially if a pituitary source is not considered. Pituitary hCG production remains largely underrecognized and can lead to unnecessary testing, harmful therapy such as chemotherapy, or delay in receiving appropriate care for other unrelated diseases. It is therefore important to establish guidelines to aid medical evaluation.
在围绝经期或绝经后的女性中，人绒毛膜促性腺激素（hCG）升高可能会引起对恶性肿瘤甚至妊娠的担忧，但由于该患者人群垂体中 hCG 的产生，也可能是良性的生理发现。诊断 hCG 升高的根本原因具有一定挑战性，特别是如果未考虑垂体来源的话。垂体 hCG 的产生在很大程度上仍未被认识到，可能导致不必要的检查、有害的治疗（如化疗），或延误对其他无关疾病的适当治疗。因此，制定有助于医学评估的指南非常重要。
